Ironwood Pharmaceuticals, Inc. develops and commercializes therapies for gastrointestinal and rare diseases. Company news centers on LINZESS® (linaclotide), its commercial product for irritable bowel syndrome with constipation and chronic idiopathic constipation, including prescription demand, U.S. net sales, label-related regulatory updates, and pediatric functional constipation data.
Recurring updates also cover apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients dependent on parenteral support. Ironwood announcements frequently include quarterly results, financial guidance, cash flow and debt commentary, medical meeting presentations, and investor communications tied to its GI-focused research and commercialization strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will present pivotal Phase III data on linaclotide for treating functional constipation in children aged 6-17 at the 2023 Digestive Disease Week® (DDW) from May 6-9 in Chicago, IL. This condition affects around 6 million children in the U.S. An oral presentation will detail a clinical trial assessing the efficacy and safety of linaclotide 72 mcg in this age group. Four poster sessions will present further efficacy and safety data. Notably, the FDA granted Priority Review for a supplemental New Drug Application (sNDA) for linaclotide in pediatric use, with a PDUFA date set for June 14, 2023. Currently, there are no FDA-approved therapies for pediatric functional constipation. Ironwood continues to expand its research in this area.
Ironwood Pharmaceuticals (Nasdaq: IRWD) will host its first quarter 2023 investor update conference call on May 4, 2023, at 8:30 a.m. Eastern Time. Participants can join by calling (888) 330-2384 (U.S./Canada) or (240) 789-2701 (international) with conference ID 4671230. The call will also be accessible via webcast on the company's website, which is recommended to access at least 15 minutes prior to the start time. A replay of the call will be available starting at 11:30 a.m. Eastern Time on the same day, and can be accessed until May 18, 2023, by calling (800) 770-2030 (U.S./Canada) or (647) 362-9199 (international), also using conference ID 4671230. Ironwood Pharmaceuticals is focused on advancing treatments for gastrointestinal diseases.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced its participation in two upcoming investor conferences:
- Cowen 43rd Annual Health Care Conference on March 6, 2023, at 9:10 a.m. ET in Boston.
- Barclays Global Healthcare Conference on March 14, 2023, at 8:00 a.m. ET in Miami.
Live webcasts of these events will be available on Ironwood's website, with replays accessible for 14 days post-conference. As a leading gastrointestinal healthcare company, Ironwood focuses on advancing treatments for GI diseases, notably through its product LINZESS® for managing IBS-C and CIC.
Ironwood Pharmaceuticals (Nasdaq: IRWD) announced its 2022 financial results, reporting a GAAP net income of $175 million and an adjusted EBITDA of $252 million. The company ended 2022 with $656 million in cash. LINZESS® U.S. net sales were $1,002 million, slightly down from 2021. The FDA granted priority review for LINZESS in pediatric patients, with a PDUFA date of June 14, 2023. The company anticipates a 3% to 5% growth in LINZESS net sales for 2023, with total revenue projections of $420 to $435 million. The fourth quarter saw total revenues of $107.2 million, a decrease from the previous year.